4a-methyloctahydronaphthalen-2(1H)-one | 57458-01-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4a-methyloctahydronaphthalen-2(1H)-one
• 英文别名: 4a-methyl-octahydro-naphthalen-2-one；1-Methyl-bicyclo<4.4.0>decan-8-on；10-Methylbicyclo<4.4.0>decan-3-on；10-Methyl-2-trans-decalon；3-Oxo-10-methyldecalin；9-Methyl-trans-decalone；4a-methyl-1,3,4,5,6,7,8,8a-octahydronaphthalen-2-one
• CAS: 57458-01-2
• 化学式: C₁₁H₁₈O
• 分子量: 166.263
• InChiKey: QAFCUHJMKAQBFU-UHFFFAOYSA-N

物化性质

• 熔点：
  47 °C
• 沸点：
  95-96 °C(Press: 3 Torr)
• 密度：
  0.979±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4a-methyloctahydronaphthalen-2(1H)-one 在 溴 、 溶剂黄146 作用下， 生成 4a-methyl-5,6,7,8-tetrahydro-2(4aH)-naphthalenone
  参考文献：
  名称：

  263.合成桑顿宁的实验。第二部分 桑托宁中含有二烯酮体系的化合物的制备

  摘要：

  DOI：

  10.1039/jr9520001437
• 作为产物：
  描述：

  4A-甲基-4,4a,5,6,7,8-六氢-3H-萘-2-酮 在 三氯化铝 、 1,3-二甲基-2-苯基-2H-苯并咪唑 作用下， 以 乙腈 为溶剂， 反应 24.0h， 以26%的产率得到4a-methyloctahydronaphthalen-2(1H)-one
  参考文献：
  名称：

  AlCl3 促进 α,β 不饱和羰基化合物与 1,3-二甲基-2-苯基苯并咪唑啉的共轭还原

  摘要：

  以1,3-二甲基-2-苯基苯并咪唑啉（DMBI）为还原剂，将除α,β-不饱和醛外的多种α,β-不饱和羰基化合物还原为相应的饱和羰基化合物在 AlCl3 的帮助下。基于 DMBI 的氢化物供体能力以及 AlCl3 作为底物的亲电活化剂的作用讨论了还原反应。发现路易斯酸的催化效率与与羰基形成络合物的效率成正比。用 2-氘代 DMBI 还原 2-肉桂酰基吡啶表明，在还原产物中，氘原子位于羰基的 β 位。另一方面，用 DMBI 还原相同的底物，然后用 D2O 淬灭，得到在 α 位含有氘标记的还原产物。这些结果被解释为涉及烯醇中间体产生的机制......

  DOI：

  10.1246/bcsj.59.1747

文献信息

• High <i>trans</i> ‐2‐Decalones by Photoredox Catalyzed β‐Isomerization
  作者：Juliette Sombret、Julie Quintaine、Tony Biremond、Quentin Barnes、Jean‐Yves Saint‐Laumer、Lionel Saudan

  DOI：10.1002/hlca.202100180

  日期：2022.1

  atom transfer (HAT) catalysis – enabled the β-isomerization of 2-decalones towards the thermodynamically most stable trans-isomers. A library of iridium (III) complexes and organic dyes were screened in combination with cyclic amines and thiols which after optimization gave the desired trans-2-decalones with high trans/cis ratios of 60 : 40 up to 98 : 2.

  三种催化过程的协同组合——光氧化还原、烯胺和氢原子转移 (HAT) 催化——使 2-decalones 的 β-异构化成为热力学上最稳定的反式异构体。结合环状胺和硫醇筛选铱 (III) 配合物和有机染料库，优化后得到所需的反式-2-癸酮，反式/顺式比例高达 60:40 至 98:2。
• PROCESS FOR PRODUCING OXYGENIC COMPOUND
  申请人：Sumitomo Chemical Company, Limited

  公开号：EP1797953B1

  公开（公告）日：2011-01-05
• Electron Transfer Mediated Photoreductions of α,β-Unsaturated Ketones
  作者：Richard S. Givens、Rominder Singh、Jieyou Xue、Young-Hee Park

  DOI：10.1016/s0040-4039(00)97173-9

  日期：1990.1
• Method for Producing Oxygen-Containing Compound
  申请人：Hagiya Koji

  公开号：US20080064898A1

  公开（公告）日：2008-03-13

  An oxidation catalyst composition is obtained by mixing a selenium compound, a nitrogen-containing aromatic compound and an acid, and if necessary, in the presence of a solvent. The oxidation catalyst composition shows an oxidation catalyst activity in the oxidation reaction of an organic compound. For example, at least one oxygen-containing compound selected from an alcohol compound, an aldehyde compound, a ketone compound and a carboxylic acid compound is obtained by reacting the olefin compound having two or more hydrogen atoms on the carbon atom at α-position of a carbon-carbon double bond with an organic hydroperoxide compound in the presence of the oxidation catalyst composition.
• [EN] C-21 THIOETHERS AS GLUCOCORTICOID RECEPTOR AGONISTS<br/>[FR] THIOÉTHERS C-21 UTILISÉS EN TANT QU'AGONISTES DU RÉCEPTEUR DE GLUCOCORTICOÏDE
  申请人：SCHERING CORP

  公开号：WO2009085880A2

  公开（公告）日：2009-07-09

  The present invention provides compounds of Formula (VII) and 11-keto analogs thereof, and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, and isomers of said compounds and said 11-keto analogs, having the general structure formula (VII): wherein L, R1, R2, R3, R4, and R5 are selected independently of each other and as defined herein. Also provided are pharmaceutical compositions, methods of preparing, and methods of using such compounds in the treatment and prophylaxis of a wide range of immune, autoimmune, and inflammatory diseases and conditions. The novel compounds of the present invention possess useful pharmacological activity while having unexpectedly low systemic activiy. Thus, the compounds of the invention represent a safer alternative to those known glucocorticoids which have poor side-effect profiles.